Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
By:
Lowey Dannenberg, P.C. via
GlobeNewswire
June 03, 2024 at 09:57 AM EDT
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for potential violations of the federal securities laws. If you suffered a loss in Akero securities, and wish to participate, learn more, or discuss the issues surrounding the investigation, please contact attorneys at (914) 733-7256 or via email to Andrea Farah (afarah@lowey.com) or Vincent R. Cappucci Jr. (vcappucci@lowey.com). About Lowey Dannenberg Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors. Contact Lowey Dannenberg P.C. SOURCE: Lowey Dannenberg
More NewsView More
The $100 Million Tell: Following Smart Money Into DoorDash ↗
Today 7:37 EST
Via MarketBeat
Wall Street’s Sleeping Giant: Is Amazon About to Wake Up? ↗
December 02, 2025
Via MarketBeat
Checkmate in the Cloud: ServiceNow's Shopping Spree ↗
December 02, 2025
Via MarketBeat
The Contrarian Case for MSTR Amid MSCI Delisting Debacle ↗
December 02, 2025
Via MarketBeat
Tickers
MSTR
Worried About Mag 7 Concentration Risk? This ETF Could Help ↗
December 02, 2025
Recent QuotesView More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
|

